TargTex and IAG, Image Analysis Group Announce Partnership

TargTex and IAG, Image Analysis Group Announce Partnership

TargTex and IAG, Image Analysis Group Announce Partnership

Lisbon, Portugal and London, UK, 8 February 2023

TargTex to partner with IAG to apply Artificial Intelligence and Advanced Imaging strategies to assess the effects of a clinical candidate in Recurrent Glioblastoma Patients

TargTex SA, a pre-clinical stage biopharmaceutical company focused on developing localized therapies for solid  tumors and IAG, Image Analysis Group, a leading global medical imaging company are collaborating to apply Artificial Intelligence (AI) and Quantitative imaging to further the development of TargTex investigational product, a hydrogel dispersed drug nanosuspension used as adjunct-to-surgery in a single dose therapy, in patients with glioblastoma multiforme (GBM).

In this collaboration, the parties will utilize AI and advanced quantitative image analysis to identify early treatment changes in GBM patients and development of predictive response markers.

Advanced imaging techniques could play a critical role in response assessment in developing new and innovative cancer therapies. Multiparametric magnetic resonance imaging (mpMRI) provides quantitative non-invasive imaging markers of early therapy-related changes.

TargTex foundation is also based on an artificial intelligence algorithm created by one of the founding members that can decipher relationships between biological targets and molecules of interest. They were able to identify an unexplored target for a daunting pathology – GBM. Considering GBM’s particularities, a hydrogel to be used as neo-adjuvant in a single dose therapy is being developed as a solution.

IAG’s advanced technology will be crucial for detection of pseudo-progression which is difficult to distinguish from true disease progression using routine clinical MRI assessment, avoid early patient withdrawal and save costs. The use of novel image analysis methodologies will allow the partners to address complex issues such as pseudo-progression and quantitatively measure the treatment response, thus deploying a truly precision medicine approach to accurately monitor patient outcomes.

IAG has deep expertise in blinded centralized reading and analysis of patient responses in real time. IAG’s scientific and medical imaging expertise in GBM, coupled with IAG’s proprietary Artificial Intelligence powered platform DYNAMIKA will allow TargTex to review efficacy assessments, and to thoroughly explore the drug effect in GBM patients.

Dr. João Seixas, CEO of TargTex, said:

“In a complex indication such as GBM it is important for us to have IAG’s expertise in advanced imaging and to employ AI tools to differentiate our program and accelerate our development through the use of predictive response markers.”

Dr. Olga Kubassova, CEO of IAG commented,

“It is our pleasure to support TargTex team who have strong foundation in biology and AI. It is our joint long-term objective to bring TargTex clinical candidates for different oncological indications through clinical development to commercialization.”

IAG’s DYNAMIKA platform is a unique comprehensible software for robust imaging data management in multi-centre trial setting and central review. Uniquely in the clinical research services industry, this is one software system to control trial progress, conduct central reads and, when needed, use built-in AI for earlier read-outs and decision support.

Use of DYNAMIKA, compliant to the industry’s highest quality certification as an integral part of our CFR21 part 11 clinical trial process, enables IAG teams to deliver high quality results, even when managing complex clinical trials that require use of advanced imaging, technical solutions and Artificial Intelligence.

Read more: DYNAMIKA, drugdevelopment, clinicaltrials, medicaldevice, MRI, CT, X-ray, fluoroscopy, PET, immunoPET, SPECT, US, histology, and DXA imaging.

Read more about IAG’s expertise in Your Therapeutic Area.

Reach our to imaging.experts@ia-grp.com

About IAG, Image Analysis Group

IAG, Image Analysis Group is a unique partner to life sciences companies. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner.

The use of novel image analysis methodologies will allow the partners to address complex issues such as pseudo-progression and quantitatively measure the treatment response, thus deploying a truly precision medicine approach to accurately monitor patient outcomes.

IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.

Learn more:  wp1.ia-grp.com

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin

 

News
Events

Congrats to IAG on BSI ISO13485 re-certification for DYNAMIKA!

Congrats to IAG on BSI ISO13485 re-certification for DYNAMIKA!

Congrats to IAG on BSI ISO13485 re-certification for DYNAMIKA!

Congratulations to IAG’s technical and quality teams for holding successful audit meetings with British Standards Institute (BSI) and receiving ISO13485 re-certification.

‘Maintenance of the highest technical standards is paramount to our company’s DNA!’ said Prof. Dehmeshki, Chief Technology Officer.

At IAG, we work to bring both CFR21 part 11 and ISO13485 quality standards into our day-to-day service and technology development, thus providing our clients with highest possible level of quality,’ said Max Feltham, IAG’s Quality Manager.

IAG’s DYNAMIKA platform is a unique comprehensible software for robust imaging data management in multi-centre trial setting and central review. Uniquely in the clinical research services industry, this is one software system to control trial progress, conduct central reads and, when needed, use built-in AI for earlier read-outs and decision support.

Use of DYNAMIKA, compliant to the industry’s highest quality certification as an integral  part of our CFR21 part 11 clinical trial process, enables IAG teams to deliver high quality results, even when managing complex clinical trials that require use of advanced imaging, technical solutions and Artificial Intelligence.

Moreover, having ISO13485 certification enables IAG to develop and release into clinical use novel methodologies, such as our AI-powered histology tool or the newest endpoint for scleroderma DAVIX.

‘IAG brings artificial intelligence in a meaningful way to the imaging process. This is the future of imaging – drives down cost and improves quality of analysis.  As images are used more for statistically meaningful endpoints, IAG has proven, validated, AI algorithms. The IAG platform and service model fits exactly with pharma efforts to be digital organizations, allowing seamless data ingestion capabilities and real time data access for analysis and decision making.’, said Dr. Olga Kubassova, IAG’s CEO.

Congratulations to the team, who will continue following ISO13485 and 21 CFR Part 11 and proceed with powering the best of pharmaceutical development, from phase 1-4!

Read more: DYNAMIKA, drugdevelopment, clinicaltrials, medicaldevice, MRI, CT, X-ray, PET, immunoPET, SPECT, US, histology, and fluoroscopy, imaging,

Read more about IAG’s expertise in Your Therapeutic Area.

Reach our to imaging.experts@ia-grp.com

About IAG, Image Analysis Group

IAG, Image Analysis Group is a unique partner to life sciences companies. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner.

The use of novel image analysis methodologies will allow the partners to address complex issues such as pseudo-progression and quantitatively measure the treatment response, thus deploying a truly precision medicine approach to accurately monitor patient outcomes.

IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.

Learn more:  wp1.ia-grp.com

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin

About ISO

ISO 13485Medical devices — Quality management systems — Requirements for regulatory purposes, is the International Standard for quality management systems for the medical devices sector. Published in 2016, it is designed to work with other management systems in a way that is efficient and transparent. The standard, which is now in its third edition, received strong support from the FDA, in line with its drive for global convergence of medical device regulatory processes.

The announcement by the FDA that it will use ISO 13485 in replacing its current quality system regulation, is an important next step in the recognition this standard has already gained globally.

News
Events

Congrats to the Team on BSI ISO13485 re-certification for DYNAMIKA!

Congrats to the Team on BSI ISO13485 re-certification for DYNAMIKA!

Congrats to the Team on BSI ISO13485 re-certification for DYNAMIKA!

Congratulations to IAG’s technical and quality teams for holding successful audit meetings with British Standards Institute (BSI) and receiving ISO13485 re-certification.

‘Maintenance of the highest technical standards is paramount to our company’s NDA!’ said Prof. Dehmeshki, Chief Technology Officer.

‘At IAG, we work to bring both CFR21 part 11 and ISO13485 quality standards into our day-to-day service and technology development, thus providing our clients with highest possible level of quality,’ said Max Feltham, IAG’s Quality Manager.

IAG’s DYNAMIKA platform is a unique comprehensible software for robust imaging data management in multi-centre trial setting and central review. Uniquely in the clinical research services industry, this is one software system to control trial progress, conduct central reads and, when needed, use built-in AI for earlier read-outs and decision support.

Use of DYNAMIKA, compliant to the industry’s highest quality certification as an integral  part of our CFR21 part 11 clinical trial process, enables IAG teams to deliver high quality results, even when managing complex clinical trials that require use of advanced imaging, technical solutions and Artificial Intelligence.

Moreover, having ISO13485 certification enables IAG to develop and release into clinical use novel methodologies, such as our AI-powered histology tool or the newest endpoint for scleroderma DAVIX.

‘We see DYNAMIKA as a unique bridge between clinical trials and clinical practice worlds. It is not trivial to translate the results of clinical trials into clinical practice. Here at IAG, we can power our pharmaceutical partners to do just that, said Dr. Olga Kubassova, IAG’s CEO.

Congratulations to the team, who will continue following ISO13485 and 21 CFR Part 11 and proceed with powering the best of pharmaceutical development, from phase 1-4!

Read more: DYNAMIKA, drugdevelopment, clinicaltrials, medicaldevice, MRI, CT, X-ray, PET, immunoPET, SPECT, US, histology, and fluoroscopy, imaging,

Read more about IAG’s expertise in Your Therapeutic Area.

Reach our to imaging.experts@ia-grp.com

About IAG, Image Analysis Group

IAG, Image Analysis Group is a unique partner to life sciences companies. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner.

The use of novel image analysis methodologies will allow the partners to address complex issues such as pseudo-progression and quantitatively measure the treatment response, thus deploying a truly precision medicine approach to accurately monitor patient outcomes.

IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.

Learn more:  wp1.ia-grp.com

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin

About ISO

ISO 13485Medical devices — Quality management systems — Requirements for regulatory purposes, is the International Standard for quality management systems for the medical devices sector. Published in 2016, it is designed to work with other management systems in a way that is efficient and transparent. The standard, which is now in its third edition, received strong support from the FDA, in line with its drive for global convergence of medical device regulatory processes.

The announcement by the FDA that it will use ISO 13485 in replacing its current quality system regulation, is an important next step in the recognition this standard has already gained globally.

News
Events

Prof. Bisdas wins Neuro-Radiologist of the Year award!

Prof. Bisdas wins Neuro-Radiologist of the Year award!

Prof. Bisdas wins Neuro-Radiologist of the Year award!

Many congratulations to Prof. Sotirios Bisdas, IAG’s Therapeutic Area Head, who received the Neuroradiologist of the Year Award in 2022, supported by the 11th International Day of Radiology #IDoR2022.

Our warmest congratulations to Prof. Bisdas, the true industry innovator and one of the most inspiring and dedicated professionals of our times!

‘Being successful in radiology takes hard work. One can’t afford to stay on autopilot in today’s rapidly changing research environments and still expect to remain on top. I believe in a culture of inclusion, purpose, support, and empathy for our consultants, academics, and clinical scientists putting patients in the centre of our work,’ said Prof. Bisdas.

Prof. Sotirios Bisdas, the Head of IAG’s Neuro-Oncology and Neuro-Degeneration is also a consultant neuroradiologist and MRI lead in the Department of Neuroradiology at the National Hospital for Neurology in London, UK, senior lecturer in neuroradiology at the Institute of Neurology University College London, and professor of radiology at Eberhard Karls University in Tübingen, Germany.

He finished his MD thesis in psychiatry after joint studies at University of Athens, Greece and University of Mainz, Germany. Dr  Bisdas was trained in Radiology and Neuroradiology at Hannover Medical School, University of Frankfurt, and University of Tübingen. He has completed a post-doctoral scholarship in Neuroradiology Research at the Medical University of South Carolina, USA. He holds a MSc degree in “Advanced Oncology” from University of Ulm, Germany and is also fellow of the European Society of Head and Neck Radiology. His expertise fields include advanced CT, intraoperative MRI, advanced and functional MRI and molecular MR-PET imaging in brain diseases.

He has authored more than 130 peer-reviewed publications (h-index > 30) and seven book chapters.

Currently, he is clinical lead of the flagship program in neuro-oncology, a joint initiative of the Institute of Healthcare Engineering and the National Hospital of Neurology and Neurosurgery. Dr Bisdas serves as member of the editorial board of several leading journals in radiology and neuroradiology, is reviewer for leading journals in neuroimaging, member of the Executive Committee of the European Society of Head and Neck Radiology, and member of the Head and Neck committee of the European Society of Neuroradiology.

About IAG, Image Analysis Group

IAG, Image Analysis Group is a unique partner to life sciences companies, leading AI-powered drug development and precision medicine. IAG leverages expertise in medical imaging and the power of DYNAMIKA™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner. IAG provides early drug efficacy assessments, smart patient recruitment, and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, and radiological expertise via risk-sharing financing and partnering models.

Learn more: wp1.ia-grp.com
Reach out: imaging.experts@ia-grp.com
Follow the Company: Linked In

News
Events

IAG is Presenting at Society of Neuro-Oncology Meeting

IAG is Presenting at Society of Neuro-Oncology Meeting

IAG is Presenting at Society of Neuro-Oncology Meeting

IAG team and Julia O’Lynn, IAG’s Director of Bio Innovation and Strategic Partnerships, will be attending the Society of Neuro-Oncology (SNO 2022) 27th Annual Meeting and Educational Day in Tampa, Florida, on November 16 – 20, 2022.

IAG’s team will be meeting with biotech companies and addressing their challenges including trial design, dealing with pseudo-progression, finding optimal endpoints to demonstrate novel therapeutics’ efficacy. We will speak about our platform DYNAMIKA and use of Artificial Intelligence in neuro-oncology trials and explore how IAG’s novel strategies, including advanced imaging biomarkers and AI can support precision medicine and drug development.

Together with our biotech partner CNS Pharmaceuticals Inc., we will be presenting the preliminary results from a  randomized, controlled trial of Berubicin.

Currently, 31 patients are enrolled with 21 in the Berubicin arm and 10 in the Lomustine arm. Trial design: https://clinicaltrials.gov/ct2/show/NCT04762069 The data available shows that Berubicin and Lomustine arms are presently balanced with relatively comparable safety profiles. This study will evaluate the efficacy of this novel drug and potentially provide therapeutic options for patients after first-line therapy.  An updated profile of the patient population, safety, and initial efficacy will be presented.

POSTER INFORMATION

A randomized, controlled trial of Berubicin, a topoisomerase II poison that crosses the blood-brain barrier (BBB), after first-line therapy for glioblastoma multiforme (GBM): Preliminary Results, Authors: S. Silberman, J. O’Lynn, O. Kubassova

If you are not attending and would like to request a poster or to schedule a call: imaging.experts@ia-grp.com

About IAG, Image Analysis Group

IAG, Image Analysis Group is a unique partner to life sciences companies, leading AI-powered drug development and precision medicine. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner. IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG partners with biotechnology and pharmaceutical companies and applies AI and Precision Medicine to accelerate drug approval.

IAG takes a holistic approach to biotech’s clinical development and brings together:

  • An efficient purpose-built cloud-based system with embedded quality controls for trial data management (DYNAMIKA)
  • Patented methodologies for quantitative assessment of treatment efficacy and safety
  • Expertise in detecting treatment effects including pseudo-progression and pseudo-response
  • Expertise to ensure regulatory compliance, targeted drug development and scientific credibility of your data
  • Ensures that its bio-pharmaceutical clients gain the greatest benefits from early objective decision making on treatment efficacy from utilizing advanced imaging techniques

About CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

About SNO, the Society for Neuro-Oncology

The Society for Neuro-Oncology exists to advance multi-disciplinary brain tumor research, education, and collaboration to drive discovery and improve patient care. click here.

Learn more: wp1.ia-grp.com
Reach out: imaging.experts@ia-grp.com
Follow the Company: Linkedin

News
Events

DAVIX – DYNAMIKA’s Novel Endpoint for Proliferation of Neointima

DAVIX – DYNAMIKA’s Novel Endpoint for Proliferation of Neointima

DAVIX – DYNAMIKA’s Novel Endpoint for Proliferation of Neointima

A collaboration between IAG, Image Analysis Group, the University of Leeds, and Prof. Francesco Del Galdo brings a new AI-driven endpoint into clinical trials.

For immediate release: 21 October 2022

Digital Artery Volume Index (DAVIX©) is a novel quantitative MRI-based scoring for the assessment of the blood flow in the arteries.

DAVIX© has been validated as a predictor of the onset of Digital Ulcers in Systemic Sclerosis patients. This innovative methodology is based on the Time-of-Flight Magnetic Resonance Imaging (MRI) angiography and allows to quantitatively assess digital arterial blood flow.

Thus, predicting the onset of Digital Ulcers (DUs) in Systemic Sclerosis (SSc) patients.

The methodology was developed as part of IAG’s DYNAMIKA cloud platform and is now accessible for use in clinical trials and clinical practice for research use. DAVIX© is being deployed by biotech and pharmaceutical companies in global clinical trials as a surrogate outcome measure of SSc vascular disease activity.

This robust methodology can be delivered to clinical sites, with over 100 imaging sites around the world already acquiring the specific MRI data to allow for the assessment of SSc patients with DAVIX©.

DAVIX© is the first MRI quantitative measure of vascular disease in Systemic Sclerosis. Building on its predictive value for active vascular disease, it is now tested in randomised clinical trials as stratification tool for vascular disease and as a surrogate endpoint for vasoactive interventions,” said Professor Francesco Del Galdo, University of Leeds.

The proprietary name of the endpoint DAVIX© has been copyrighted by the University of Leeds, with a lifetime licence assigned to IAG, Image Analysis Group.

“We look forward to seeing how this unique endpoint will help accelerating the speed of pharmaceutical R&D and most importantly improve therapeutic success for patients,“  said Dr. Olga Kubassova, CEO of IAG, Image Analysis Group.

Neointima proliferation results in vascular wall thickening and gradual loss of luminal patency and is a key pathological feature of Systemic Sclerosis. It is a recognised culprit pathological lesion in Digital Ulcers, pulmonary hypertension and renal crisis.

We are delighted with the results of this collaboration. DAVIX© fits perfectly with IAG’s suite of advanced Artificial Intelligence (AI)-supported imaging methodologies and our strategy to make DYNAMIKA™ the leading image management platform for forward thinking drug developers, said Simon Hart, IAG’s Bio-Partnering Director.

IAG’s has brought technical capabilities and over 15 years of operational experience helping to optimize and standardize DAVIX© in clinical trials. This is a great compliment to all IAG’s teams involved into developing and deploying our Artificial Intelligence methodologies, across hundreds of globally distributed clinical sites, built on our DYNAMIKA™, IAG’s proprietary secure cloud based medical image management and review platform, “ added Prof. Jamshid Dehmeshki, CTO of IAG.  

About IAG, Image Analysis Group

IAG, Image Analysis Group is a unique partner to life sciences companies, leading AI-powered drug development and precision medicine. IAG leverages expertise in medical imaging and the power of DYNAMIKA™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner. IAG provides early drug efficacy assessments, smart patient recruitment, and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, and radiological expertise via risk-sharing financing and partnering models.

Learn more: wp1.ia-grp.com
Reach out: imaging.experts@ia-grp.com
Follow the Company: Linked In

News
Events

AltruBio and IAG, Image Analysis Group Announce Partnership

AltruBio and IAG, Image Analysis Group Announce Partnership

AltruBio and IAG, Image Analysis Group Announce Partnership

SAN FRANCISCO, May 08, 2023 – AltruBio Inc. (“AltruBio” or “the Company”), a clinical-stage biotech company specializing in the development of novel therapeutics for the treatment of immunological diseases with high unmet medical needs, today announced a joint poster presentation with their partner Image Analysis Group (IAG) at the Digestive Disease Week® conference, held at McCormick Place in Chicago, IL, from May 6-9, 2023.

David T. Rubin, M.D., Professor of Medicine and Pathology at the University of Chicago and AltruBio Scientific Advisory Board member, will present proof of concept data utilizing a novel AI-powered method developed by IAG for the analysis of patient tissue from AltruBio’s Phase 2b open label study of immune checkpoint enhancer (ICE) ALTB-168, in patients with moderately to severely active anti-TNFα and/or anti-integrin refractory ulcerative colitis (UC).

“Using AI tools for histology simplifies the interpretation of histological samples and offers promise in establishing a new gold standard of histological assessment in clinical trials, as well as providing earlier signals for interpretation beneficial to both patients and scientists,” said Dr. Rubin.

Jesse Hall, M.D., Chief Medical Officer of AltruBio, added,

“IAG’s AI-powered technology accurately supports histological assessment of treatment response to our ICE in development. We plan to continue clinical validation of targeting PSGL-1 to treat autoimmune and inflammatory diseases and share further progress this year.”

Key data highlights include an 87% correlation between AI Tool-determined Nancy Indices and those conducted by an expert pathologist. The AI Tool also demonstrated a 93% decrease in automatically detected neutrophils for subjects who achieved clinical remission.

Poster Presentation Details:

Session Title: AGA IBD: Disease Activity Assessment Session Date & Time: May 8, 2023 from 12:30 PM to 1:30 PM CDT (UTC –5) Presentation Title: A Novel AI Tool is Accurate at Interpreting Histology and Detects Response to ALTB-168 Therapy in Patients with Moderate to Severe Ulcerative Colitis: Proof of Concept

About AltruBio Inc.

AltruBio is a privately held biotechnology company headquartered in San Francisco that focuses on developing novel therapeutics for the treatment of immunological diseases with high unmet medical needs. Its first-generation molecule, ALTB-168, has achieved proof of mechanism in four autoimmune and inflammatory diseases. The next-generation ICE, ALTB-268, is currently being evaluated in a Phase 1 clinical trial.

About Digestive Disease Week Digestive Disease Week®

DDW is the largest international gathering of physicians, researchers, and academics in the fields of gastroenterology, hepatology, endoscopy, and gastrointestinal surgery. The conference showcases more than 3,100 abstracts and hundreds of lectures on the latest advances in GI research, medicine, and technology. More information can be found at www.ddw.org.

About IAG, Image Analysis Group:

IAG, Image Analysis Group is a unique clinical development partner to life sciences companies. We broadly leverage our proprietary image analysis methodologies, power of our cloud platform DYNAMIKA, years of experience in AI and Machine Learning as well as bespoke co-development business models to ensure higher probability for promising therapeutics to reach the patients. Our independent Bio-Partnering division fuses risk-sharing business models and agile culture to accelerate novel drug development. wp1.ia-grp.com

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin

News
Events

Meet IAG’s Team at DDW 2022, San Diego

Meet IAG’s Team at DDW 2022, San Diego

Meet IAG’s Team at DDW 2022, San Diego

Dr. Olga Kubassova, IAG’s CEO, and Simon Hart, IAG’s Bio-partnering Director, will be attending the Digestive Disease Week 2022 (DDW 2022) conference in San Diego, on May 21 – 24, 2022.

IAG’s team will be meeting with key biotech companies and addressing the challenges they face in pharmaceutical trials to explore IAG’s novel strategies, including advanced imaging biomarkers and Artificial Intelligence in precision medicine and drug development.

If you are not attending, schedule a call: imaging.experts@ia-grp.com

IAG partners with biotechnology and pharmaceutical companies and applies AI and Precision Medicine to accelerate drug approval.

IAG takes a holistic approach to biotech’s clinical development and brings together:

  • An efficient purpose-built cloud-based system with embedded quality controls for trial data management (DYNAMIKA)
  • Patented methodologies for quantitative assessment of treatment efficacy and safety
  • Expertise in detecting treatment effects including pseudo-progression and pseudo-response
  • Expertise to ensure regulatory compliance, targeted drug development and scientific credibility of your data
  • Ensures that its bio-pharmaceutical clients gain the greatest benefits from early objective decision making on treatment efficacy from utilizing advanced imaging techniques

Discover our risk assessment and management strategies to overcome the challenges in your trial by contacting IAG at imaging.experts@ia-grp.com

About DDW

Digestive Disease Week (DDW) is the most prestigious meeting in the world for GI professionals providing an unparalleled opportunity to delve into exciting new developments with leaders in gastroenterology, hepatology, endoscopy and gastrointestinal surgery. To find out more about this conference click here.

About Image Analysis Group (IAG)

IAG, Image Analysis Group is a unique partner to life sciences companies, leading AI-powered drug development and precision medicine. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner. IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.

Learn more: wp1.ia-grp.com
Reach out: imaging.experts@ia-grp.com
Follow the Company: Linkedin

News
Events

Meet IAG’s Team at EULAR 2022, Copenhagen

Meet IAG’s Team at EULAR 2022, Copenhagen

Meet IAG’s Team at EULAR 2022, Copenhagen

Dr. Olga Kubassova, IAG’s CEO, will be attending the European Congress of Rheumatology (EULAR 2022) in in Copenhagen, on June 1 – 4, 2022.

IAG’s team will be meeting with key biotech companies and addressing the challenges they face in pharmaceutical trials to explore IAG’s novel strategies, including advanced imaging biomarkers and Artificial Intelligence in precision medicine and drug development.

POSTER INFORMATION

Use of Artificial Intelligence and cloud-based infrastructure to improve the speed and accuracy of eligibility reads in osteoarthritis trials. POS1127

M. Boesen, C. Pereira da Costa, J. O’Lynn, A. Patterson, D. Kessler, O. Kubassova

If you are not attending, schedule a call: imaging.experts@ia-grp.com

IAG partners with biotechnology and pharmaceutical companies and applies AI and Precision Medicine to accelerate drug approval.

IAG takes a holistic approach to biotech’s clinical development and brings together:

  • An efficient purpose-built cloud-based system with embedded quality controls for trial data management (DYNAMIKA)
  • Patented methodologies for quantitative assessment of treatment efficacy and safety
  • Expertise in detecting treatment effects including pseudo-progression and pseudo-response
  • Expertise to ensure regulatory compliance, targeted drug development and scientific credibility of your data
  • Ensures that its bio-pharmaceutical clients gain the greatest benefits from early objective decision making on treatment efficacy from utilizing advanced imaging techniques

Discover our risk assessment and management strategies to overcome the challenges in your trial by contacting IAG at imaging.experts@ia-grp.com

About EULAR

European Congress of Rheumatology (EULAR 2022) is one of the the most prestigious meetings in the world for rheumatology providing a forum of an unparalleled opportunity to the highest standard for scientific, both clinical and basic, educational and social exchange between professionals.

To find out more about this conference click here.

About Image Analysis Group (IAG)

IAG, Image Analysis Group is a unique partner to life sciences companies, leading AI-powered drug development and precision medicine. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner. IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.

Learn more: wp1.ia-grp.com
Reach out: imaging.experts@ia-grp.com
Follow the Company: Linkedin

News
Events